Zacks Investment Research upgraded shares of Compugen Ltd. (NASDAQ:CGEN) from a hold rating to a buy rating in a report issued on Tuesday. Zacks Investment Research currently has $7.00 price target on the stock.
According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “
Separately, FBR & Co reissued a buy rating on shares of Compugen in a report on Wednesday, June 22nd. Six research analysts have rated the stock with a buy rating, Compugen currently has an average rating of Buy and an average price target of $10.40.
Compugen (NASDAQ:CGEN) traded up 0.97% during trading on Tuesday, reaching $6.25. 39,953 shares of the company’s stock were exchanged. Compugen has a 52 week low of $4.32 and a 52 week high of $7.79. The stock has a 50-day moving average of $6.82 and a 200-day moving average of $6.66. The stock’s market capitalization is $318.18 million.
Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.04. Compugen had a negative return on equity of 26.46% and a negative net margin of 245.83%. On average, equities research analysts anticipate that Compugen will post ($0.56) EPS for the current year.
Several large investors have recently added to or reduced their stakes in CGEN. ProShare Advisors LLC boosted its stake in Compugen by 0.8% in the second quarter. ProShare Advisors LLC now owns 37,652 shares of the company’s stock valued at $244,000 after buying an additional 300 shares during the period. Vident Investment Advisory LLC bought a new stake in Compugen during the second quarter valued at approximately $522,000. Janney Montgomery Scott LLC boosted its stake in Compugen by 2.2% in the second quarter. Janney Montgomery Scott LLC now owns 45,787 shares of the company’s stock valued at $293,000 after buying an additional 1,000 shares during the period. Vanguard Group Inc. boosted its stake in Compugen by 12.4% in the second quarter. Vanguard Group Inc. now owns 740,047 shares of the company’s stock valued at $4,796,000 after buying an additional 81,729 shares during the period. Finally, Rothschild Investment Corp IL boosted its stake in Compugen by 2.2% in the second quarter. Rothschild Investment Corp IL now owns 458,510 shares of the company’s stock valued at $2,971,000 after buying an additional 10,000 shares during the period. Institutional investors and hedge funds own 14.09% of the company’s stock.
Compugen Company Profile
Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.